Open AccessPI3K inhibitors are finally coming of age
Author(s) -
Bart Vanhaesebroeck,
Matthew W. D. Perry,
Jennifer R. Brown,
Fabrice André,
Klaus Okkenhaug
Publication year - 2021
Publication title -
nature reviews. drug discover/nature reviews. drug discovery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 9.921
H-Index - 328
eISSN - 1474-1784
pISSN - 1474-1776
DOI - 10.1038/s41573-021-00209-1
Subject(s) - pi3k/akt/mtor pathway , cancer , medicine , pharmacology , cancer research , biology , signal transduction , biochemistry
Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has been hampered by issues such as poor drug tolerance and drug resistance, several PI3K inhibitors have now received regulatory approval - the PI3Kα isoform-selective inhibitor alpelisib for the treatment of breast cancer and inhibitors mainly aimed at the leukocyte-enriched PI3Kδ in B cell malignancies. In addition to targeting cancer cell-intrinsic PI3K activity, emerging evidence highlights the potential of PI3K inhibitors in cancer immunotherapy. This Review summarizes key discoveries that aid the clinical translation of PI3Kα and PI3Kδ inhibitors, highlighting lessons learnt and future opportunities.